➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Mallinckrodt
McKesson
Moodys
Medtronic

Last Updated: October 20, 2021

DrugPatentWatch Database Preview

ZEGALOGUE (AUTOINJECTOR) Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Zegalogue (autoinjector), and what generic alternatives are available?

Zegalogue (autoinjector) is a drug marketed by Zealand Pharma and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-one patent family members in twenty-three countries.

The generic ingredient in ZEGALOGUE (AUTOINJECTOR) is dasiglucagon hydrochloride. Additional details are available on the dasiglucagon hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Zegalogue (autoinjector)

Zegalogue (autoinjector) will be eligible for patent challenges on March 22, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

Indicators of Generic Entry

< Available with Subscription >

  Free Forever Trial

Summary for ZEGALOGUE (AUTOINJECTOR)
International Patents:31
US Patents:1
Applicants:1
NDAs:1
DailyMed Link:ZEGALOGUE (AUTOINJECTOR) at DailyMed
Drug patent expirations by year for ZEGALOGUE (AUTOINJECTOR)

US Patents and Regulatory Information for ZEGALOGUE (AUTOINJECTOR)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zealand Pharma ZEGALOGUE (AUTOINJECTOR) dasiglucagon hydrochloride SOLUTION;SUBCUTANEOUS 214231-002 Mar 22, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Zealand Pharma ZEGALOGUE (AUTOINJECTOR) dasiglucagon hydrochloride SOLUTION;SUBCUTANEOUS 214231-002 Mar 22, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Mallinckrodt
McKesson
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.